Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Comprehensive Genomic Profiling May Identify Select Subsets in Ovarian Cancer

August 7th 2017

Julia A. Elvin, MD, PhD, discusses genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.

Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer

August 2nd 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

Maintenance Olaparib Data Published as FDA Weighs Approval

August 1st 2017

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

AstraZeneca: Pioneers in Ovarian Cancer

July 18th 2017

Since the approval of LYNPARZA, over 3,000 US women with germline BRCA-mutated advanced ovarian cancer have been treated with this important medicine.

Emerging Novel Agents for Ovarian Cancer

July 14th 2017

Potential for Immunotherapy in Ovarian Cancer

July 14th 2017

Sequencing for Treatment for Recurrent Ovarian Cancer

July 14th 2017

Difference Among PARP Inhibitors for Ovarian Cancer

July 14th 2017

Niraparib Maintenance for Recurrent Ovarian Cancer

July 14th 2017

Rucaparib for Recurrent Ovarian Cancer

July 14th 2017

Olaparib Maintenance for Recurrent Ovarian Cancer

July 14th 2017

When to Add Bevacizumab for Recurrent Ovarian Cancer

July 14th 2017

Secondary Debulking in Recurrent Ovarian Cancer

July 14th 2017

Key Considerations for Treating Recurrent Ovarian Cancer

July 14th 2017

Upfront Antiangiogenic Therapy in Advanced Ovarian Cancer

July 14th 2017

Optimizing Chemotherapy for Advanced Ovarian Cancer

July 14th 2017

Lymph Node Dissection for Ovarian Cancer

July 14th 2017

Somatic Mutation Testing for Ovarian Cancer

July 14th 2017

BRCA Testing in Ovarian Cancer

July 14th 2017

Therapy Combinations May Become the Treatment of Choice in Ovarian Cancer

July 12th 2017

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.